Ferreira, DanielRivero-Santana, AmadoPerestelo-Pérez, LilisbethWestman, EricWahlund, Lars-OlofSarria-Santamera, AntonioSerrano-Aguilar, Pedro2020-04-242020-04-242014Front Aging Neurosci. 2014 Oct 16;6:287.1663-4365http://hdl.handle.net/20.500.12105/9733BACKGROUND: Cerebrospinal fluid (CSF) biomarkers' performance for predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is still suboptimal. OBJECTIVE: By considering several confounding factors we aimed to identify in which situations these CSF biomarkers can be useful. DATA SOURCES: A systematic review was conducted on MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane, and CRD (1990-2013). ELIGIBILITY CRITERIA: (1) Prospective studies of CSF biomarkers' performance for predicting conversion from MCI to AD/dementia; (2) inclusion of Aβ42 and T-tau and/or p-tau. Several meta-analyses were performed. RESULTS: Aβ42/p-tau ratio had high capacity to predict conversion to AD in MCI patients younger than 70 years. The p-tau had high capacity to identify MCI cases converting to AD in ≤24 months. CONCLUSIONS: Explaining how different confounding factors influence CSF biomarkers' predictive performance is mandatory to elaborate a definitive map of situations, where these CSF biomarkers are useful both in clinics and research.engVoRhttp://creativecommons.org/licenses/by/4.0/Alzheimer’s diseaseCSF biomarkersConfounding factorsMeta-analysisMild cognitive impairmentSystematic reviewAtribución 4.0 Internacional25360114628710.3389/fnagi.2014.00287Frontiers in aging neuroscienceopen access